Biopharmaceutical company focused on neurodegenerative diseases,including ALS
| Year | Firm | Period | Expenses | Doc |
|---|---|---|---|---|
| 2024 | CAPITOL HILL CONSULTING GROUP |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
— | |
| 2024 | CAPITOL HILL CONSULTING GROUP |
1st Quarter (Jan 1 - Mar 31) Registration |
— |
| Firm | Filings | Expenses |
|---|---|---|
| CAPITOL HILL CONSULTING GROUP | 12 | — |
| Issue | Activities |
|---|---|
| Health Issues | 12 |